SpringerLink
Log in

The Emerging Role of Local Therapy in Metastatic Prostate Cancer

  • Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer.

Recent Findings

The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligometastatic HSPC, and showed an improvement in hormone therapy–free survival.

Summary

Local prostate radiotherapy should be offered to patients with newly diagnosed low volume metastatic HSPC. Early clinical evidence suggests that local treatment to metastatic disease might be beneficial for patients with oligometastatic HSPC, but larger trials are awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.

    Article  Google Scholar 

  2. Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67(1):3–6.

    Article  Google Scholar 

  3. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.

    Article  Google Scholar 

  4. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(24):2835–42.

    Article  CAS  Google Scholar 

  5. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63.

    Article  Google Scholar 

  6. Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671.

    Article  Google Scholar 

  7. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7.

    Article  CAS  Google Scholar 

  8. Morgan SC, Parker CC. Local treatment of metastatic cancer--killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011;8(8):504–6.

    Article  Google Scholar 

  9. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285–93.

    Article  CAS  Google Scholar 

  10. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35–44.

    Article  CAS  Google Scholar 

  11. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–75.

    Article  CAS  Google Scholar 

  12. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.

    Article  CAS  Google Scholar 

  13. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013;155(4):750–64.

    Article  CAS  Google Scholar 

  14. Gužvić M, Klein CA. The biology of cancer metastasis. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 117–28.

  15. Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16(1):176.

    Article  Google Scholar 

  16. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–7.

    Article  CAS  Google Scholar 

  17. •• Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England). 2018;392(10162):2353–66. Practice changing randomized controlled phase 3 trial showing that local radiotherapy improves overall survival in newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer.

  18. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.

    Article  Google Scholar 

  19. • Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410–8. Randomized controlled phase 3 trial investigating local radiotherapy to the prostate in newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

    Article  Google Scholar 

  20. • Burdett S, Boeve LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol. 2019;76(1):115–24. Meta-analysis of the STAMPEDE and the HORRAD data, confirming that local radiotherapy improves overall survival in newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer.

    Article  Google Scholar 

  21. Cytoreductive prostatectomy versus cytoreductive prostate irradiation as a local treatment option for metastatic prostate cancer: a multicentric feasibility trial (LoMP II) 2018 [Available from: https://clinicaltrials.gov/ct2/show/NCT03655886.

  22. SWOG1802 Phase III Randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer [Available from: https://www.swog.org/clinical-trials/s1802.

  23. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    Article  Google Scholar 

  24. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–26.

    Article  Google Scholar 

  25. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  Google Scholar 

  26. Ali A, Hoyle AP, James ND, Parker CC, Brawley CC, Attard G, Douis H, Mason M, Parmar MK, Sydes MR, Clarke NW, and the STAMPEDE investigators. Exploratory analysis of metastatic site and number in the STAMPEDE M1/RT comparison. Presented at ESMO 2019.

  27. • Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(5):446–53. Randomized phase 2 trial suggesting that local treatment of metastases in patients with hormone-sensitive oligometastatic prostate cancer might be beneficial.

    Article  CAS  Google Scholar 

  28. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393(10185):2051–8.

    Article  Google Scholar 

  29. Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82.

    Article  CAS  Google Scholar 

  30. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(18):1558–65.

    Article  CAS  Google Scholar 

  31. Patel PH, Palma D, McDonald F, Tree AC. The Dandelion Dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clinical oncology (Royal College of Radiologists (Great Britain)). 2019.

  32. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–12.

    Article  CAS  Google Scholar 

  33. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415.

    Article  CAS  Google Scholar 

  34. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2017;67(1):65–85.

    Article  Google Scholar 

  35. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.

    Article  Google Scholar 

  36. Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol. 2019;75(5):707–11.

    Article  CAS  Google Scholar 

  37. Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, et al. Circulating tumor DNA abundance and potential utility in De novo metastatic prostate cancer. Eur Urol. 2019;75(4):667–75.

    Article  CAS  Google Scholar 

  38. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–708.

    Article  CAS  Google Scholar 

  39. Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018;143(5):1236–48.

    Article  CAS  Google Scholar 

  40. Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444–57.

    Article  CAS  Google Scholar 

  41. Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7(312):312re10-re10.

  42. Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9(1):1176.

    Article  Google Scholar 

Download references

Acknowledgements

AT acknowledges the support of the Rosetrees Trust. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Author information

Authors and Affiliations

  1. Urological Oncology Department, Royal Marsden Hospital, Downs Road, Sutton, London, SM2 5PT, UK

    Nora Sundahl, Alison Tree & Chris Parker

  2. Radiotherapy and Imaging Division, Institute of Cancer Research, Sutton, London, UK

    Nora Sundahl, Alison Tree & Chris Parker

Authors
  1. Nora Sundahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alison Tree
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chris Parker.

Ethics declarations

Conflict of Interest

Nora Sundahl has received travel support from Bayer, MSD, Bristol-Myers Squibb, and Astellas.

Alison Tree has received research funding from Elekta, Accuray, and MSD; and has received travel support and honoraria from Janssen, Bayer, Astellas, Ferring, Bayer, and Elekta.

Chris Parker has received compensation from AAA Pharmaceutical, Bayer, and Janssen for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sundahl, N., Tree, A. & Parker, C. The Emerging Role of Local Therapy in Metastatic Prostate Cancer. Curr Oncol Rep 22, 2 (2020). https://doi.org/10.1007/s11912-020-0868-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-0868-1

Keywords

Search

Navigation